Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

80 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Ipragliflozin, a sodium-glucose cotransporter 2 inhibitor, reduces bodyweight and fat mass, but not muscle mass, in Japanese type 2 diabetes patients treated with insulin: A randomized clinical trial.
Inoue H, Morino K, Ugi S, Tanaka-Mizuno S, Fuse K, Miyazawa I, Kondo K, Sato D, Ohashi N, Ida S, Sekine O, Yoshimura M, Murata K, Miura K, Arima H, Maegawa H; SUMS-ADDIT-1 Research group. Inoue H, et al. Among authors: miyazawa i. J Diabetes Investig. 2019 Jul;10(4):1012-1021. doi: 10.1111/jdi.12985. Epub 2019 Jan 21. J Diabetes Investig. 2019. PMID: 30536746 Free PMC article. Clinical Trial.
Liver fat accumulation assessed by computed tomography is an independent risk factor for diabetes mellitus in a population-based study: SESSA (Shiga Epidemiological Study of Subclinical Atherosclerosis).
Fuse K, Kadota A, Kondo K, Morino K, Fujiyoshi A, Hisamatsu T, Kadowaki S, Miyazawa I, Ugi S, Maegawa H, Miura K, Ueshima H; SESSA Research Group. Fuse K, et al. Among authors: miyazawa i. Diabetes Res Clin Pract. 2020 Feb;160:108002. doi: 10.1016/j.diabres.2020.108002. Epub 2020 Jan 3. Diabetes Res Clin Pract. 2020. PMID: 31904446
The Prognosis of Patients With Type 2 Diabetes and Nonalbuminuric Diabetic Kidney Disease Is Not Always Poor: Implication of the Effects of Coexisting Macrovascular Complications (JDDM 54).
Yokoyama H, Araki SI, Kawai K, Yamazaki K, Shirabe SI, Sugimoto H, Minami M, Miyazawa I, Maegawa H; JDDM Study Group. Yokoyama H, et al. Among authors: miyazawa i. Diabetes Care. 2020 May;43(5):1102-1110. doi: 10.2337/dc19-2049. Epub 2020 Mar 6. Diabetes Care. 2020. PMID: 32144168
Metabolic changes induced by dapagliflozin, an SGLT2 inhibitor, in Japanese patients with type 2 diabetes treated by oral anti-diabetic agents: A randomized, clinical trial.
Horibe K, Morino K, Miyazawa I, Tanaka-Mizuno S, Kondo K, Sato D, Ohashi N, Ida S, Yanagimachi T, Yoshimura M, Itoh R, Murata K, Miura K, Arima H, Fujita Y, Ugi S, Maegawa H; SUMS-ADDIT-2 Research group. Horibe K, et al. Among authors: miyazawa i. Diabetes Res Clin Pract. 2022 Apr;186:109781. doi: 10.1016/j.diabres.2022.109781. Epub 2022 Feb 15. Diabetes Res Clin Pract. 2022. PMID: 35181350 Clinical Trial.
Total energy expenditure is comparable between patients with and without diabetes mellitus: Clinical Evaluation of Energy Requirements in Patients with Diabetes Mellitus (CLEVER-DM) Study.
Morino K, Kondo K, Tanaka S, Nishida Y, Nakae S, Yamada Y, Ugi S, Fuse K, Miyazawa I, Ohi A, Nishida K, Kurihara M, Sasaki M, Ebine N, Sasaki S, Katsukawa F, Maegawa H. Morino K, et al. Among authors: miyazawa i. BMJ Open Diabetes Res Care. 2019 Mar 25;7(1):e000648. doi: 10.1136/bmjdrc-2019-000648. eCollection 2019. BMJ Open Diabetes Res Care. 2019. PMID: 31114702 Free PMC article.
Relationship between Kidney Function and Subclinical Atherosclerosis Progression Evaluated by Coronary Artery Calcification.
Ganbaatar N, Kadota A, Hisamatsu T, Araki SI, Kume S, Fujiyoshi A, Kadowaki S, Torii S, Kondo K, Segawa H, Salman E, Miyazawa I, Yamamoto T, Nakagawa Y, Maegawa H, Miura K, Ueshima H. Ganbaatar N, et al. Among authors: miyazawa i. J Atheroscler Thromb. 2022 Sep 1;29(9):1359-1371. doi: 10.5551/jat.63030. Epub 2021 Oct 22. J Atheroscler Thromb. 2022. PMID: 34690221 Free PMC article.
80 results